(via NewsDirect)
Daugaard tells Proactive the data describes the progress of the company’s kt-3000 drug development program. The data shows the kt-3000 prototype lead candidate exhibits higher PARP-1 versus PARP-2 selectivity compared to the FDA-approved PARP inhibitor, olaparib.
Daugaard also says the kt-3000 lead candidate effectively reduced lung metastases in mice inoculated with Ewing sarcoma tumor cells.
Contact Details
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source